Pharmaceutical Executive, Feb 1, 2014 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Feb 1, 2014
Features
The Active Patient: Faces Of Change
By Ben Comer
Advocacy organizations and individual patients are getting more involved in every facet of the healthcare system, from drug R&D, to federal and state policy all fueled by the hour-to-hour passion of living with a disease.
Will Europe's Regulatory Watchdog Come Of Age In 2014?
By Reflector
Reflector looks at the growing pains of the European Medicine Agency (EMA) as it faces key policy challenges of 2014.
Takeda's Oncology Taskmaster
By William Looney
Millennium Takeda's new president, Anna Protopapas, explains the life choices that brought her from Cyprus to Cambridge—and a lead position in the hotly contested search to make cancer a treatable disease.
Product Positioning 2.0
By Stan Bernard, MD
Industry and market transformations have dramatically altered when and how products should be positioned for launch, writes Stan Bernard.
Managed Markets: Positioning Your Product For Success with Pull Through Strategies
By Partha Anbil
A patient-centric approach to drug development delivers the benefits that actually create value.
From the Editor
A Spark From GSK
By William Looney
Today, there is promise in new approaches that rely on the "other language of biology," using the human body's own circuitry of cells and nerves to induce precisely targeted therapeutic effects against a range of debilitating diseases.
Feature
Social Media: Have We Reached The Tipping Point?
For pharma marketers, the good news is recent advances in social media monitoring make it possible to listen to or engage with patients on social media websites.
Country Report
Country Philippines
Connecting the Dots The inclusion of healthcare as a priority on the presidential agenda has led to knock-on consequences that are being felt across the healthcare value chain in the Philippines. Universal healthcare coverage (UHC) has been cemented, which has led to a shift from branded medicines to generics, leading many players to a strategic repositioning. The most successful players have been those who focused on a strategy that was inclusive of all stakeholders and aligned with the presidential agenda of affordable and accessible healthcare.
Column
Russian Innovation: A Higher Mark
By William Looney
For the first time, the spotlight shines on Russia's potential in biotechnology and pharma products
Drug Coverage, Costs Under Scrutiny
By Jill Wechsler
Benefits offered by insurance plans on health exchanges and through Medicare are raising concerns about patient access to needed therapies, writes Jill Wechsler.

ADVERTISEMENT

Click here